Last reviewed · How we verify
Celebrex and Metformin for Postoperative Hepatocellular Carcinoma (XBD)
This prospective trial aims to compare the role of celebrex alone, metformin alone, and celebrex plus metformin in preventing HCC recurrence after hepatic resection.
Details
| Lead sponsor | Guangxi Medical University |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 200 |
| Start date | 2017-06-02 |
| Completion | 2021-06 |
Conditions
- Liver Cancer
Interventions
- Celebrex plus Metformin
- Celebrex
- Metformin
Primary outcomes
- Number of participants with tumor recurrence — 1-year
The 1-year tumor recurrence will be compared between the three groups
Countries
China